Trial Profile
A Phase 1, Safety, Tolerability and Pharmacokinetic Profile Study of Intravenous Injections of HB002.1T (a Vascular Endothelial Growth Factor Receptor Decoy) in Subjects With Solid Tumor
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs HB-002T (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Huabo Biopharm
- 26 Jul 2021 Status changed from active, no longer recruiting to completed.
- 11 Mar 2021 Planned End Date changed from 28 Feb 2021 to 28 Aug 2021.
- 11 Mar 2021 Planned primary completion date changed from 1 Feb 2021 to 6 Jun 2021.